Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

La Colaboración Hugo RAS Colorrectal (HRCC)

5 de noviembre de 2026 actualizado por: Matteo Rottoli, IRCCS Azienda Ospedaliero-Universitaria di Bologna

El Hugo RAS Colorectal Collaborative (HRCC): Un estudio internacional para avanzar la cirugía mínimamente invasiva

The Hugo RAS Colorectal Collaborative (HRCC) is an international, multicenter dataset of patients undergoing colorectal surgery using the Hugo RAS system. The registry aims to analyze short and long-term outcomes to provide real-world evidence on the safety and effectiveness of the system.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

This prospective observational study will gather data via standardized electronic Case Report Forms (eCRFs) across multiple international high-volume colorectal surgery centers. The study intends to foster the standardization of surgical techniques, evaluate the learning curve of surgeons, and identify surgical best practices for the Hugo RAS modular system. The total expected duration for the initial phase is approximately 3 years, followed by extended long-term follow-up.

Tipo de estudio

De observación

Inscripción (Estimado)

2000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adult patients (≥18 years) undergoing any type of elective or emergent colorectal surgery using the Hugo RAS system. The population will be drawn from participating high-volume colorectal surgery centers across multiple countries. All eligible patients at these centers will be enrolled to minimize selection bias.

Descripción

Inclusion Criteria:

  • Adult patients (age ≥ 18 years)
  • Scheduled to undergo any type of colorectal surgery (elective or emergent) where the Hugo RAS system is planned to be used
  • Willing and able to provide written informed consent

Exclusion Criteria:

-Patients unable to provide informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: OTHER

Cohortes e Intervenciones

Grupo / Cohorte
Patients undergoing Hugo RAS colorectal surgery

Adult patients (≥18 years) scheduled to undergo any type of elective or emergent colorectal surgery utilizing the Hugo™ RAS (Robotic-Assisted Surgery) System at participating high-volume colorectal surgery centers. The intervention of interest is the use of the Hugo RAS System, a medical device manufactured by Medtronic, which consists of a surgeon console, robotic arms with instrument manipulators, and a vision cart. The system is intended for performing minimally invasive colorectal surgical procedures. Because this is an observational study, patients will receive treatment according to the standard clinical practice of the participating centers.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Complications
Periodo de tiempo: Intraoperatively

Number of participants experiencing intraoperative complications, which will include the recording of robotic arm conflicts, system alarms (including red alarms), and any technical difficulties encountered.

Intraoperatively
Rate of Postoperative Complications
Periodo de tiempo: Postoperatively (30-day and 90-day)

Number and severity of postoperative complications assessed using the Clavien-Dindo classification system

Postoperatively (30-day and 90-day)
Operative Time
Periodo de tiempo: Intraoperatively

Total duration in minutes of the surgical procedure measured to evaluate the efficacy of the Hugo RAS system.

Intraoperatively
Blood loss
Periodo de tiempo: Intraoperatively.

Measurement of blood loss during the surgical procedure. (ml)

Intraoperatively.
Conversion Rate
Periodo de tiempo: Intraoperatively.

Measurement of conversion rates to open or traditional laparoscopic surgery (%)

Intraoperatively.
Length of Hospital Stay
Periodo de tiempo: At discharge, assessed up to 90 days post-surgery

Total length (days) of patient hospital stay post-surgery.

At discharge, assessed up to 90 days post-surgery
Hospital Readmission Rate
Periodo de tiempo: Up to 90 days post-surgery

Rate of hospital readmissions following discharge.

Up to 90 days post-surgery
Pathological Outcomes: Margin Status and Lymph Node Yield
Periodo de tiempo: Up to 30 days post-surgery

Assessment of pathological outcomes, specifically evaluating margin status and lymph node yield.

Up to 30 days post-surgery
Disease Recurrence Rate
Periodo de tiempo: Up to 5 years post-surgery

Monitoring of disease recurrence rates post-surgery.

Up to 5 years post-surgery
Overall and Disease-Free Survival
Periodo de tiempo: Up to 5 years post-surgery

Collection of survival data, specifically overall survival and disease-free survival rates.

Up to 5 years post-surgery
Long-term Functional Outcomes
Periodo de tiempo: Long-term follow-up (e.g., 1 year, 3 years post-surgery).

Assessment of long-term functional outcomes, such as bowel function.

Long-term follow-up (e.g., 1 year, 3 years post-surgery).
Bowel Function Assessed by the LARS Score
Periodo de tiempo: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery

Bowel function will be evaluated using the unabbreviated Low Anterior Resection Syndrome (LARS) score questionnaire. The total score ranges from 0 to 42. A score of 0 to 20 indicates no LARS, 21 to 29 indicates minor LARS, and 30 to 42 indicates major LARS. Higher scores indicate worse bowel function and a worse outcome.

Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
Fecal Incontinence Assessed by the Wexner Scale
Periodo de tiempo: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery

Fecal incontinence will be evaluated using the Cleveland Clinic (Wexner) Fecal Incontinence Score. The scale assesses the frequency of different types of incontinence and lifestyle alterations. The total score ranges from 0 to 20, where 0 represents perfect continence and 20 represents complete incontinence. Higher scores indicate more severe incontinence and a worse outcome.

Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
Quality of Life Assessed by the EORTC QLQ-C30
Periodo de tiempo: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery

Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). All scale and single-item measures are linearly transformed to a score ranging from 0 to 100. For the global health status and functional scales, a higher score represents a better level of functioning and a better quality of life. For the symptom scales and items, a higher score represents a higher level of symptomatology and a worse quality of life.

Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
Health-Related Quality of Life Assessed by the EQ-5D-3L
Periodo de tiempo: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery

Health status will be evaluated using the EuroQol-5 Dimension-3 Level (EQ-5D-3L) questionnaire. This tool consists of a descriptive system and a Visual Analogue Scale (VAS). The descriptive system assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, which are converted into a single health utility index score (typically ranging from less than 0 to 1.0, where 1.0 represents full health). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0 to 100. For both the index score and the VAS, higher scores indicate a better health status and a better outcome.

Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de noviembre de 2026

Finalización primaria (Estimado)

1 de marzo de 2029

Finalización del estudio (Estimado)

1 de junio de 2029

Fechas de registro del estudio

Enviado por primera vez

20 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de abril de 2026

Publicado por primera vez (Actual)

21 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de marzo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • HRCC

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Requests for access to anonymized individual patient-level data by external researchers will be considered on a case-by-case basis by the HRCC steering committee. A formal data sharing agreement outlining the terms of use, data security, and publication policies will be required. The primary aim is to protect patient confidentiality and ensure that data is used responsibly for advancing scientific knowledge in line with the registry's objectives.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .